10 likes | 186 Views
ENDEAVOR II. Target vessel failure at 9 months: 7.9% for Endeavor vs. 15.1% for Driver Target lesion revascularization at 9 months: 4.6% vs. 11.8% (p = 0.0001), respectively Death: 1.2% vs. 0.5% (p = 0.34), respectively Stent thrombosis: 0.5% vs. 1.2%, respectively.
E N D
ENDEAVOR II Target vessel failure at 9 months: 7.9% for Endeavor vs. 15.1% for Driver Target lesion revascularization at 9 months: 4.6% vs. 11.8% (p = 0.0001), respectively Death: 1.2% vs. 0.5% (p = 0.34), respectively Stent thrombosis: 0.5% vs. 1.2%, respectively Trial design: Stable patients with native coronary disease were randomized to DES (n = 598) versus BMS (n = 599). Primary outcome was target vessel failure at 9 months. Results (p = 0.0001) 15.1 % 7.9 (p = 0.22) Conclusions • Among stable patients undergoing PCI for a single de novo lesion, the use of the Endeavor drug-eluting stent was beneficial. • This stent reduced target vessel failure and target lesion revascularization compared with a Driver bare-metal stent. 1.2 0.5 Target vessel failure Stent thrombosis DES BMS Fajadet J, et al. Circulation 2006;114:798-806